Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Palmar-plantar erythrodysesthesia")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 8 of 8

  • Page / 1
Export

Selection :

  • and

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Recall following different chemotherapy agentsYUK FUNG HUI; GILES, Francis J; CORTES, Jorge E et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 49-53, issn 0167-6997, 5 p.Article

Pegylated liposomal doxorubicin-associated hand-foot syndrome : Recommendations of an international panel of expertsVON MOOS, Roger; THUERLIMANN, Beat J. K; LADEMANN, Jürgen et al.European journal of cancer (1990). 2008, Vol 44, Num 6, pp 781-790, issn 0959-8049, 10 p.Article

Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemiaBINGNAN ZHANG; BOLOGNIA, Jean; MARKS, Peter et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 303-307, issn 0344-5704, 5 p.Article

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and SunitinibLIPWORTH, Adam D; ROBERT, Caroline; ZHU, Andrew X et al.Oncology. 2009, Vol 77, Num 5, pp 257-271, issn 0030-2414, 15 p.Article

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer : results of a multicenter phase-II trialSEHOULI, J; OSKAY-ÖZCELIK, G; LICHTENEGGER, W et al.Annals of oncology. 2006, Vol 17, Num 6, pp 957-961, issn 0923-7534, 5 p.Article

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysisVISWANATH REDDY BELUM; SHENHONG WU; LACOUTURE, Mario E et al.Investigational new drugs. 2013, Vol 31, Num 4, pp 1078-1086, issn 0167-6997, 9 p.Article

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancerAL-BATRAN, Salah-Eddin; MEERPOHL, Hans-Gerd; JAGER, Elke et al.Oncology. 2006, Vol 70, Num 2, pp 141-146, issn 0030-2414, 6 p.Article

Biweekly Pegylated Liposomal Doxorubicin as Second-line Treatment in Patients with Relapsed Ovarian Cancer after Failure of Platinum and Paclitaxel : Results from a Multi-center Phase II Study of the NOGGOOSKAY-OEZCELIK, Guelten; KOENSGEN, Dominique; HINDENBURG, Hans-Joachim et al.Anticancer research. 2008, Vol 28, Num 2B, pp 1329-1334, issn 0250-7005, 6 p.Article

  • Page / 1